BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
81 results:

  • 1. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
    Abdelbaky SB; Giacopelli B; Rabe KG; Yamaguchi K; Wu YZ; Yan H; Shanafelt TD; Parikh SA; Ding W; Hampel PJ; Brown S; Cerhan JR; Vachon CM; Kay NE; Hanson CA; Parker AS; Braggio E; Slager SL; Oakes CC
    Blood; 2024 Apr; 143(17):1752-1757. PubMed ID: 38194687
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genomics and transcriptomic alterations of the glutamate receptors in acute myeloid leukemia.
    Alqahtani A; Wang M; Lou M; Alachkar H
    Clin Transl Sci; 2023 Oct; 16(10):1828-1841. PubMed ID: 37670476
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
    Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
    Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
    Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
    Dekker L; Calkoen FG; Jiang Y; Blok H; Veldkamp SR; De Koning C; Spoon M; Admiraal R; Hoogerbrugge P; Vormoor B; Vormoor HJ; Visscher H; Bierings M; Van Der Vlugt M; Van Tinteren H; Nijstad AL; Huitema ADR; Van Der Elst KCM; Pieters R; Lindemans CA; Nierkens S
    Blood Adv; 2022 Apr; 6(7):1969-1976. PubMed ID: 35134115
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
    Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
    Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
    Badar T; Szabo A; Litzow M; Burkart M; Yurkiewicz I; Dinner S; Hefazi M; Shallis RM; Podoltsev N; Patel AA; Curran E; Wadleigh M; Balasubramanian S; Yang J; Arslan S; Aldoss I; Mattison R; Cenin D; Siebenaller C; Advani A; Liedtke M; Atallah E
    Bone Marrow Transplant; 2021 Aug; 56(8):1998-2004. PubMed ID: 33824440
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
    Kim HT; Shaughnessy CJ; Rai SC; Reynolds C; Ho VT; Cutler C; Koreth J; Gooptu M; Romee R; Nikiforow S; Armand P; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Brown JR
    Blood Adv; 2020 Sep; 4(17):4113-4123. PubMed ID: 32882002
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Elsayed AH; Rafiee R; Cao X; Raimondi S; Downing JR; Ribeiro R; Fan Y; Gruber TA; Baker S; Klco J; Rubnitz JE; Pounds S; Lamba JK
    Leukemia; 2020 Mar; 34(3):735-745. PubMed ID: 31645648
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
    Michallet M; Chapuis-Cellier C; Dejoie T; Lombard C; Caillon H; Sobh M; Moreau P; Attal M; Avet-Loiseau H
    Leukemia; 2018 Feb; 32(2):376-382. PubMed ID: 28663581
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
    Badar T; Kantarjian HM; Nogueras-Gonzalez GM; Borthakur G; Garcia Manero G; Andreeff M; Konopleva M; Kadia TM; Daver N; Wierda WG; Luthra R; Patel K; Oran B; Champlin R; Ravandi F; Cortes JE
    Am J Hematol; 2015 Nov; 90(11):1065-70. PubMed ID: 26299958
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid leukemia: A Report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    Clin Cancer Res; 2015 Jul; 21(14):3187-95. PubMed ID: 25825478
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
    Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
    Claus R; Lucas DM; Ruppert AS; Williams KE; Weng D; Patterson K; Zucknick M; Oakes CC; Rassenti LZ; Greaves AW; Geyer S; Wierda WG; Brown JR; Gribben JG; Barrientos JC; Rai KR; Kay NE; Kipps TJ; Shields P; Zhao W; Grever MR; Plass C; Byrd JC
    Blood; 2014 Jul; 124(1):42-8. PubMed ID: 24868078
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.
    Fehér C; Rovira M; Soriano A; Esteve J; Martínez JA; Marco F; Carreras E; Martínez C; Fernández-Avilés F; Suárez-Lledó M; Mensa J
    J Antimicrob Chemother; 2014 Sep; 69(9):2556-62. PubMed ID: 24855125
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.